论文部分内容阅读
多年来,β—内酰胺类抗生素为临床上应用极为广泛的抗感染抗生素,在长期使用中,导致致病菌耐药现象日趋严重。据1981年11月在日内瓦由世界卫生组织召开的十二国专家会议上指出,近年来,由于微生物耐药能力增大,有些国家的医生将无法再用抗生素去治疗更多的疾病,如青霉素在有些国家内己不能治疗肺炎及淋病等疾病,其产生耐药性的主要原因是因为这些耐药菌产生能催化β—内酰胺抗生素水解的一种β—内酰胺酶,以致用
Over the years, β-lactam antibiotics are clinically used widely anti-infective antibiotics, resulting in long-term use, leading to the growing resistance of pathogens. According to a meeting of 12 experts convened by WHO in November 1981 in Geneva, it has been pointed out in some countries that doctors will no longer be able to use antibiotics to treat more diseases in recent years due to increased microbial resistance such as penicillin In some countries, treatment of diseases such as pneumonia and gonorrhea can not be treated. The main reason for its resistance is that these resistant bacteria produce a β-lactamase that catalyzes the hydrolysis of β-lactam antibiotics,